Evidence map›Paper›PMID 30115656›Full record

ArticleHaematologica2019

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Arnon P Kater, Marinus H J van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F M Posthuma, Martin Schipperus, Martine E D Chamuleau, Marcel Nijland, Jeanette K Doorduijn and 12 more

Open access · goldAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Maintenance therapy for chronic lymphocytic leukaemia.The Cochrane database of systematic reviews · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 3 countries.

Arnon P KaterDepartment of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam a.p.kater@amc.uva.nl.
Marinus H J van OersDepartment of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam.
Yvette van NordenDepartment of Hematology - HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam.
Lina van der StratenDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
Julia DriessenDepartment of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam.
Ward F M PosthumaDepartment of Internal Medicine, Reinier de Graaf Hospital, Delft.
Martin SchipperusDepartment of Hematology, Haga Hospital, the Hague.
Martine E D ChamuleauDepartment of Hematology, VU University Medical Center, Amsterdam.
Marcel NijlandDepartment of Hematology, University Medical Center, Groningen.
Jeanette K DoorduijnDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam.
Michel Van GelderDepartment of Hematology, Maastricht University Medical Center.
Mels HoogendoornDepartment of Internal Medicine, Medical Center, Leeuwarden.
Francien De CroonDepartment of Internal Medicine, Ikazia Hospital, Rotterdam.
Shulamiet WittebolDepartment of Internal Medicine, Gelderland Valley Hospital, Ede.
J Martijn KerstDepartment of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam.
Erik W A MarijtDepartment of Hematology, Leiden University Medical Center.
Reinier A P RaymakersDepartment of Hematology, University Medical Center, Utrecht.
Martijn R SchaafsmaDepartment of Hematology, Medical Spectrum Twente, Enschede.
Johan A DobberLaboratory Special Hematology, Academic Medical Center, Amsterdam, the Netherlands.
Sabina KerstingDepartment of Hematology, Haga Hospital, the Hague.
Mark-David LevinDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
HOVON CLL study group
Academic Medical Center · NLAlbert Schweitzer Hospital · GAErasmus MC Cancer Institute · NLHaga Hospital · NLLeiden University Medical Center · NLIkazia Ziekenhuis · NLMaastricht University · NLMedisch Centrum Leeuwarden · NLMedisch Spectrum Twente · NLThe Netherlands Cancer Institute · NLUniversity Hospital and Clinics · USUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NLZiekenhuis Gelderse Vallei · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m

Indexed as

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChlorambucilDisease-Free SurvivalFeasibility StudiesFemaleHumansLenalidomideLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedRituximabSurvival RateVidarabineChlorambucilfludarabineLenalidomideRituximabVidarabine

Identifiers

PMID30115656
PMCPMC6312018
OpenAlexW2885601672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.